News | April 26, 2024
Laurus Labs posts Q4 FY24 consolidated PAT at Rs. 75.61 Cr
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Laurus Labs has reported total income of Rs. 1,458.20 crores during the period ended March 31, 2024
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Around 7% of the Indian population suffers from IBS
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Sun Pharma's Dadra facility receives OAI status from US FDA
Subscribe To Our Newsletter & Stay Updated
